Combination of low-dose glucocorticosteroids and mineralocorticoids as adjunct therapy for adult patients with septic shock: A systematic review and meta-analysis of randomized trials and observational studies

Abstract

Background: The role of the combination of glucocorticosteroids and mineralocorticosteroids in treating septic shock is not well-defined. The aim of this study was to perform a systematic review and meta-analysis of the randomized controlled trials and observational studies assessing the effect of low-dose hydrocortisone and fludrocortisone on patients with septic shock. Materials and Methods: MEDLINE, Scopus, and Cochrane databases were reviewed. A random effect model meta-analysis was used and I-square was used to assess the heterogeneity. Short-term mortality was chosen as our primary end point. A subgroup analysis was performed including only the randomized controlled trials. Results: A total of 10,550 patients were included in this meta-analysis. Administration of the steroid combination was associated with improved short-term mortality (odds ratio, 0.78, confidence interval, 0.64–0.96), intensive care unit mortality, and shock reversal, without increase in steroid-related side effects, such as secondary infection or gastrointestinal hemorrhage. Conclusion: This systematic review and meta-analysis showed that use of the combination of glucocorticosteroids and mineralocorticosteroids has a beneficial impact on short-term mortality, intensive care unit mortality, and shock reversal, without increasing the incidence of gastrointestinal hemorrhage or superinfection in patients with septic shock, when used as an adjunct treatment to the established standard of care.

Keywords

Fludrocortisone - glucocorticosteroids - hydrocortisone - mineralocorticoids - septic shock - steroids

• References

• 1 Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R. et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43: 304-77
• 2 Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10
• 3 Bruno JJ, Dee BM, Anderegg BA, Hernandez M, Pravinkumar SE. et al. US practitioner opinions and prescribing practices regarding corticosteroid therapy for severe sepsis and septic shock. J Crit Care 2012; 27: 351-61
• 1 Laviolle B, Donal E, Le MaguetP, Lainé F, Bellissant E. et al. Low doses of fludrocortisone and hydrocortisone, alone or in combination, on vascular responsiveness to phenylephrine in healthy volunteers. Br J Clin Pharmacol 2013; 75: 423-30
• 5 Laviolle B, Nesseler N, Massart C, Bellissant E. et al. Fludrocortisone and hydrocortisone, alone or in combination, on in vivo hemodynamics and in vitro vascular reactivity in normal and endotoxemic rats: A randomized factorial design study. J Cardiovasc Pharmacol 2014; 63: 488-96
• 6 Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S. et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 2018; 378: 809-18
• 7 Sinha S, Riley RD, Higgins JP, Deeks JJ. et al. Interpretation of random effects meta-analyses. BMJ 2011; 342: d549
• 8 Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71
• 9 Bauer SR, Lam SW, Cha SS, Oyen LJ. et al. Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: A case control study. J Crit Care 2008; 23: 500-6
• 10 Beale R, Janes JM, Brunkhorst FM, Dobb G, Levy MM, Martin GS. et al. Global utilization of low-dose corticosteroids in severe sepsis and septic shock: A report from the PROGRESS registry. Crit Care 2010; 14: R102
• 11 Rygård SL, Butler E, Granholm A, Møller MH, Cohen J, Finfer S. et al. Low-dose corticosteroids for adult patients with septic shock: A systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2018; 44: 1003-16
• 12 Sharshar T, Gray F, Lorin de la GrandmaisonG, Hopkinson NS, Ross E, Dorandeu A. et al Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet 2003; 362: 1799-805
• 13 Polito A, Sonneville R, Guidoux C, Barrett L, Viltart O, Mattot V. et al. Changes in CRH and ACTH synthesis during experimental and human septic shock. PLoS One 2011; 6: e25905
• 14 Annane D, Maxime V, Ibrahim F, Alvarez JC, Abe E, Boudou P. Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am J Respir Crit Care Med 2006; 174: 1319-26
• 15 Polito A, Lorin de la GrandmaisonG, Mansart A, Louiset E, Lefebvre H, Sharshar T. et al. Human and experimental septic shock are characterized by depletion of lipid droplets in the adrenals. Intensive Care Med 2010; 36: 1852-8
• 16 Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A. et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med 2017; 43: 1751-63
• 17 Funder JW. Aldosterone and mineralocorticoid receptors—Physiology and pathophysiology. Int J Mol Sci 2017; 18: 1032
• 18 Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B. et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 2005; 19: 1697-710
• 19 Wildling L, Hinterdorfer P, Kusche-Vihrog K, Treffner Y, Oberleithner H. et al. Aldosterone receptor sites on plasma membrane of human vascular endothelium detected by a mechanical nanosensor. Pflugers Arch 2009; 458: 223-30
• 20 Fadel F, André-Grégoire G, Gravez B, Bauvois B, Bouchet S, Sierra-Ramos C. et al. Aldosterone and vascular mineralocorticoid receptors in murine endotoxic and human septic shock. Crit Care Med 2017; 45: e954-62
• 21 Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE. et al. Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor. Science 1987; 237: 268-75
• 22 Druce LA, Thorpe CM, Wilton A. et al. Mineralocorticoid effects due to cortisol inactivation overload explain the beneficial use of hydrocortisone in septic shock. Med Hypotheses 2008; 70: 56-60
• 23 Funder JW. et al. Apparent mineralocorticoid excess. J Steroid Biochem Mol Biol 2017; 165: 151-3
• 24 Gomez-Sanchez E, Gomez-Sanchez CE. et al. The multifaceted mineralocorticoid receptor. Compr Physiol 2014; 4: 965-94
• 25 Sinha S, Fjeld CC, Birdsong WT, Goodman RH. et al. Differential binding of NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal binding protein to serve as a metabolic sensor. Proc Natl Acad Sci U S A 2003; 100: 9202-7
• 26 Zhou MY, Gomez-Sanchez EP, Cox DL, Cosby D, Gomez-Sanchez CECloning. expression, and tissue distribution of the rat nicotinamide adenine dinucleotide-dependent 11 beta-hydroxysteroid dehydrogenase. Endocrinology 1995; 136: 3729-34
• 27 Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R. et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med 2018; 378: 797-808
• 28 Annane D, Cariou A, Maxime V, Azoulay E, D’honneur G, Timsit JF. et al Corticosteroid treatment and intensive insulin therapy for septic shock in adults: A randomized controlled trial. JAMA 2010; 303: 341-8